In addition, HER2/neu (ErbB2), EGFR (ErbB1), HER3 (ErbB3), and HER4 (ErbB4) are members of the ErbB receptor-tyrosine kinase (RTK) family, and the oncogenic mutation patterns of EGFR and HER2 provide attractive options for targeted NSCLC therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.